Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line (original) (raw)

Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma

Lisa Winkelmayer

Cells

View PDFchevron_right

Quantitative proteomic analysis of post-translational modifications of human histones

Hans Beck, Rune Matthiesen

Molecular & Cellular …, 2006

View PDFchevron_right

Directing The Role of Histone Deacetylase Inhibitors in Cancer Therapy: A Review

Bhavini Gharia

2019

View PDFchevron_right

A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells

Anna Maria Timperio

2008

View PDFchevron_right

Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

Saverio Minucci

Molecular Cancer Therapeutics, 2013

View PDFchevron_right

Quantitative Proteomic Analysis of Histone Modifications

Benjamín García

Chemical reviews, 2015

View PDFchevron_right

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

Lise Gjerdrum

Histopathology, 2008

View PDFchevron_right

Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A

Yiannis Ninios

View PDFchevron_right

Histone deacetylases and epigenetic therapies of hematological malignancies

Ciro Mercurio

Pharmacological research : the official journal of the Italian Pharmacological Society, 2010

View PDFchevron_right

The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma

Owen O'Connor

British Journal of Haematology, 2015

View PDFchevron_right

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

Jasmine Zain

Investigational New Drugs, 2010

View PDFchevron_right

Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells

Takashi Okamoto

Leukemia, 2007

View PDFchevron_right

Targeting histone deacetylase in cancer therapy

Chang-shi Chen

Medicinal Research Reviews, 2006

View PDFchevron_right

Differential protein acetylation induced by novel histone deacetylase inhibitors

Keith Glaser

Biochemical and Biophysical Research Communications, 2004

View PDFchevron_right

Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents

Alfredo Budillon

Recent Patents on Anti-Cancer Drug Discovery, 2007

View PDFchevron_right

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Christine Tam

Journal of Biological Chemistry, 2013

View PDFchevron_right

Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line

Maarten Dhaenens

International journal of molecular sciences, 2014

View PDFchevron_right

Current perspective of histone deacetylase inhibitors: A review

IP Innovative Publication Pvt. Ltd.

IP Innovative Publication Pvt. Ltd., 2018

View PDFchevron_right

Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation

Alain Verreault

Scientific reports, 2012

View PDFchevron_right

Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma

Michael Lairmore

Leukemia Research - LEUK RES, 2011

View PDFchevron_right

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

Victoria Luchenko

Molecular Pharmaceutics, 2011

View PDFchevron_right

Histone Deacetylase Inhibitor Pharmacodynamic Analysis by Multiparameter Flow Cytometry

Judith Karp

Annals of Clinical and Laboratory Science, 2005

View PDFchevron_right

Histone Deacetylase Inhibitors in Cancer Therapy: Latest Developments, Trends and Medicinal Chemistry Perspective

Andrew Lane

Anti-Cancer Agents in Medicinal Chemistry, 2007

View PDFchevron_right

Site-specific quantification of lysine acetylation in the N-terminal tail of histone H4 using a double-labelling, targeted UHPLC MS/MS approach

Annalisa D'Urzo

Analytical and bioanalytical chemistry, 2016

View PDFchevron_right

Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin

Thomas Litman

Molecular oncology, 2014

View PDFchevron_right